ArticleTranslational vision science & technology2024
Clinical Validation of M-TONX: A Novel Combo Rebound Tonometer and Pachymeter.
Article in Translational vision science & technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trial
- Clinical Assessment of Automated Non-Contact Tonometer: Interchangeability with Goldmann Applanation Tonometry and Repeatability.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to perform a clinical investigation of an innovative rebound technology-based device, the M-TONX, to simultaneously measure intraocular pressure (IOP) and central corneal thickness (CCT). Methods: The IOP and CCT of the patients were first measured by the M-TONX. Then, the measurements were repeated by the Goldman applanation (GAT) and the Pentacam corneal topographer, as the standard devices. For the statistical analysis, the patients were stratified based on their IOPs to group 1 (IOP < = 16 millimeters of mercury [mm Hg]), group 2 (16 mm Hg < IOP < 23 mm Hg), and group 3 (IOP > = 23 mm Hg). The stratification was also performed for the CCTs as: class 1 (CCT < = 475 µm), class 2 (475 < CCT < 574 µm), and class 3 (CCT > = 575 µm). Results: Of the 374 eyes (225 subjects and 43% women), 262, 66, and 46 eyes belonged to group 1, group 2, and group 3, respectively. Very high IOP (>35 mm Hg) was observed in 12 eyes. The overall confidence interval of the deviation (confidence level = 95%) from the standard devices was estimated to be 0.7 to 1.2 mm Hg for IOP, and -12.7 to -5.4 µm for CCT. The stratified analysis showed substantial agreement with the standard devices with the intraclass correlation > 0.65 and the Pearson Correlation > 0.8 calculated for all the groups and classes. Conclusions: The M-TONX exhibited a reliable performance concerning the standards for measuring IOP and CCT. Its accuracy remains stable for a broad range of IOP and CCT. The M-TONX successfully incorporates two separate functionalities into a single compact user-friendly device. Translational Relevance: This study uncovers the conformity of the technology with the standards, linking fundamental research to clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.